GGrantIndex
← Search

UCCRC-Cancer Center Support Grant

$266,581P30FY2001CANIH

University Of Chicago, Chicago IL

Investigators

Linked publications, trials & patents

Paper 39661064Paper 39579248Paper 39438113Paper 39374047Paper 39270007Paper 39141403Paper 39114540Paper 39108474Paper 39071306Paper 39069988Paper 38883758Paper 38881356Paper 38849889Paper 38810242Paper 38771643Paper 38752924Paper 38735044Paper 38716867Paper 38691450Paper 38632339Paper 38561491Paper 38548994Paper 38536082Paper 38533736Paper 38496521Paper 38427437Paper 38421866Paper 38381713Paper 38294692Paper 38294689Paper 38293065Paper 38219706Paper 38213818Paper 38190286Paper 38186960Paper 38175791Paper 38155245Trial NCT02573363Trial NCT02573220Trial NCT02542202Trial NCT02540876Trial NCT02485535Trial NCT02420210Trial NCT02399371Trial NCT02389517Trial NCT02366819Trial NCT02333188Trial NCT02333162Trial NCT02275533Trial NCT02258659Trial NCT02213913Trial NCT02199665Trial NCT02122172Trial NCT02046421Trial NCT02012296Trial NCT01949740Trial NCT01861301Trial NCT01696955Trial NCT01576172Trial NCT01307618Trial NCT01281176Trial NCT01278615Trial NCT01267266Trial NCT01256385Trial NCT01208051Trial NCT01174264Trial NCT01122888Trial NCT01076543Trial NCT01064622Trial NCT00859937Trial NCT00720174Trial NCT00504153Trial NCT00436579Trial NCT00387335Trial NCT00381641Trial NCT00376688Trial NCT00369551Trial NCT00351975Trial NCT00303862Trial NCT00290472Trial NCT00265798Trial NCT00126542Trial NCT00095784Trial NCT00091026Trial NCT00087373Trial NCT00062075Trial NCT00058019Trial NCT00055913Trial NCT00039416Trial NCT00027703Trial NCT00023946Patent 7192711Patent 6870037Patent 6482934Patent 6387619Patent 6043216Patent 5916752Patent 5786344Patent 5698686Patent 5618917

Abstract

This application requests continuing support for the Cancer Research Center at the University of Chicago (UCCRC). Clinical and laboratory research is organized into five established programs (Molecular Biology of Cell Growth and Differentiation; Cancer Molecular Genetics; lmmunology and Cancer; Clinical and Experimental Therapeutics, Advanced Imaging) and three developing programs (Breast Cancer, Prostate Cancer, Prevention and Control). Clinical research is a major focus of multidisciplinary activity at the UCCRC. More than 800 patients are enrolled annually on clinical research protocols supported by cooperative agreements to conduct phase I phase II and phase III clinical trials. The UCCRC is the host institution for the Cancer and Leukemia Group B (CALGB) and also participates in the Radiation Therapy Oncology Group, the Gynecologic Oncology Group and the Children's Cancer Group. Funds are requested in this application for Senior Leadership, Program Leaders, Planning and Evaluation, Developmental Funds, Administration, Pilot Trials, the Clinical Protocol Review and Monitoring System and eleven shared resources (Transgenic Mouse/Embryonic Stem Cell Facility; Animal Barrier Facility; DNA Sequencing Facility; Oligopeptide Synthesis Facility; Flow Cytometry and lmmunohistochemistry Facility; Electron Microscopy Facility; NMR Spectroscopy Facility; Monoclonal Antibody Facility; Pharmacology Core Facility; Protocol and Data Management Office and Biostatistics Facility). The overall goals of the UCCRC are (1) to stimulate and support collaborative interdisciplinary laboratory research in cancer; (2) to advance discoveries and new treatment strategies from the laboratory to clinical application; (3) to apply modern techniques of molecular biology, genetics and cytogenetics to the study of human tumors; (4) to conduct multidisciplinary clinical treatment programs for patients with cancer; (5) to provide education and training in cancer research for basic scientists, clinical investigators and health care professionals at all levels of training; (6) to provide access to clinical trials to community oncologists and minority populations via a network of affiliated hospitals and (7) to initiate cancer prevention and control research at the University of Chicago and the Chicago metropolitan area.

View original record on NIH RePORTER →